MyFinsight
Home
Blog
About
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$169,143K
Free Cash flow
$50,072K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Purchases of short-term investme...
Net loss
Sale of short-term investments
Others
Negative Cash Flow Breakdown
Maturities of short-term investm...
Accrued expenses and other curre...
Non-cash lease expense
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-09-30
2025-06-30
Net loss
57,863
-26,925
-50,795
Depreciation and amortization
-525
256
496
Non-cash loss on sale of property and equipment
153
-
-
Net (accretion) and amortization of investments in marketable securities
40
-204
528
Non-cash lease expense
-879
567
894
Stock-based compensation expense
-6,201
4,735
8,429
Accounts receivable
58
-
-
Prepaid expenses and other current assets
-3,424
-2,534
5,144
Other assets
-1,256
362
548
Accounts payable
1,268
-179
1,216
Accrued expenses and other current liabilities
-5,971
1,696
784
Operating lease liabilities
579
-9
111
Net cash used in operating activities
49,711
-17,465
-45,307
Purchases of short-term investments
-127,343
101,620
56,093
Sale of short-term investments
10,075
-
-
Maturities of short-term investments
-86,689
44,978
100,033
Purchases of property and equipment
-361
134
313
Net cash provided by investing activities
51,090
-56,776
43,627
Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs
-
269,834
-
Payment of deferred offering costs
210
-
63
Proceeds from exercise of stock options
167
636
6
Repurchase of unvested restricted common stock
4
0
1
Net cash provided by financing activities
-269,944
270,533
-58
Net increase in cash, cash equivalents, and restricted cash
-169,143
196,292
-1,738
Cash, cash equivalents, and restricted cash at beginning of period
251,464
56,910
-
Cash, cash equivalents, and restricted cash at end of period
78,161
251,464
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Purchases of short-term
investments
-$127,343K
Net loss
$57,863K
Sale of short-term
investments
$10,075K
Purchases of property and
equipment
-$361K
Prepaid expenses and
other current assets
-$3,424K
Accounts payable
$1,268K
Other assets
-$1,256K
Non-cash loss on sale of
property and equipment
$153K
Net cash provided by
investing activities
$51,090K
Net cash used in
operating activities
$49,711K
Canceled cashflow
$86,689K
Canceled cashflow
$14,253K
Net increase in
cash, cash...
-$169,143K
Canceled cashflow
$100,801K
Proceeds from exercise of
stock options
$167K
Maturities of short-term
investments
-$86,689K
Stock-based compensation
expense
-$6,201K
Accrued expenses and
other current...
-$5,971K
Non-cash lease expense
-$879K
Operating lease
liabilities
$579K
Depreciation and
amortization
-$525K
Accounts receivable
$58K
Net (accretion) and
amortization of investments...
$40K
Net cash provided by
financing activities
-$269,944K
Canceled cashflow
$167K
something is missing
-$269,897K
Payment of deferred
offering costs
$210K
Repurchase of unvested
restricted common stock
$4K
Buy us a coffee